O6-Methylguanine DNA Methyltransferase (MGMT) Expression and Ki-67 Index Predict Response to Temozolomide in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDPNET)

#842

Introduction: Temozolomide (TEM) showed encouraging results in WDPNET. Decreased MGMT expression and methylation of its promoter seems to correlate with better outcome in TEM-treated glioblastomas.

Aim(s): To assess if MGMT expression and the methylation of its promoter can predict the efficacy of TEM in WDPNET.

Materials and methods: Patients with WDPNET treated with TEM between 2006-2012 were included. Treatment efficacy was assessed by the best radiological response (RECIST criteria). Expression of MGMT was assessed by an immunochemistry score based on intensity (0 to 3) x % of stained cells [0- 300]. MGMT promoter methylation was assessed by pyrosequencing.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Cros J

Authors: Cros J, Hentic O, Rebours V, Zappa M, Maire F,

Keywords: MGMT, pancreatic NET, temozolomide,